Skip to main content
Top
Published in:

Open Access 03-01-2024 | Entrectinib | Correction

Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

Authors: Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi

Published in: Oncology and Therapy | Issue 1/2024

Login to get access

Excerpt

Correction: Oncol Ther https://doi.org/10.1007/s40487-023-00251-6
Metadata
Title
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer
Authors
Giulio Metro
Eleonora Gariazzo
Silvia Costabile
Sara Baglivo
Fausto Roila
Francesca Colamartini
Barbara Palumbo
Pietro Chiarini
Stefania Gori
Antonio Conti
Luca Marcomigni
Guido Bellezza
Gianluigi Lunardi
Publication date
03-01-2024
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 1/2024
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-023-00258-z

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now